Ubenimex is reported to reverse multidrug resistance (MDR) of HCC by suppressing Pim3, BCL-2, and BCL-XL expression, decreasing Bad phosphorylation and further enhancing tumor cell apoptosis [173]. Here, BCL2 is linked to hepatocellular carcinoma.